Breaking News Instant updates and real-time market news.

GEMP

Gemphire Therapeutics

$7.32

-0.21 (-2.79%)

16:00
08/06/18
08/06
16:00
08/06/18
16:00

Gemphire Therapeutics trading halted, news pending

GEMP Gemphire Therapeutics
$7.32

-0.21 (-2.79%)

07/27/18
ROTH
07/27/18
NO CHANGE
Target $40
ROTH
Buy
Gemphire Therapeutics price target raised to $40 from $30 at Roth Capital
Roth Capital analyst Yasmeen Rahimi raised her price target for Gemphire Therapeutics to $40 from $30 based on a positive forecast for the company's lead molecule in the pediatric NASH trial. In a research note to investors, Rahimi projects $415M peak sales for gemcabene for pediatric NASH in the U.S. in 2028 based on assumptions that include ~7.5M children with NAFLD among which 25% progress to NASH of which 12% have advanced NASH, as well as a U.S. launch in 2022 in 4% with peak market penetration of 55%. Rahimi, who has a Buy rating on Gemphire, sees top-line six-month histology results for the 24-week Phase 2a study in eight NASH patients with familial partial lipodystrophy in the fall, which will give clearer and early indications of gemcabene's effects on biopsy.
05/16/18
RAJA
05/16/18
INITIATION
Target $22
RAJA
Outperform
Gemphire Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Laura Chico initiated Gemphire Therapeutics with an Outperform and $22 price target saying its gemcabene offs a potentially differentiated profile in the dyslipidemia space, which should narrow the gap versus peers with successful data.
01/26/18
HCWC
01/26/18
NO CHANGE
Target $28
HCWC
Buy
Gemphire Therapeutics price target raised to $28 from $22 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Gemphire Therapeutics to $28 saying he sees a "catalyst-rich" 2018 for the company. The analyst says his confidence grows in the emerging multiple mechanisms of the compound as the gemcabene pipeline expands. He keeps a Buy rating on Gemphire Therapeutics.
12/22/17
ROTH
12/22/17
NO CHANGE
Target $30
ROTH
Buy
Gemphire transition to NASH a value creator, says Roth Capital
Roth Capital analyst Yasmeen Rahimi views Gemphire Therapeutics' transition into non-alcoholic steatohepatitis as an "important shareholder value creator." After the company announced the launch of proof-of-concept Phase 2a trial of gemacabene in eight patients with familial partial lipodystrophy, a rare genetic metabolic condition characterized by abnormal distribution of subcutaneous fat which then leads to NASH, the analyst keeps a Buy rating on Gemphire with a $30 price target.

TODAY'S FREE FLY STORIES

YEXT

Yext

$23.00

0.33 (1.46%)

22:43
03/18/19
03/18
22:43
03/18/19
22:43
Syndicate
Yext 6.1M share Spot Secondary priced at $21.50 »

Goldman Sachs is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

WU

Western Union

$18.17

-0.2 (-1.09%)

22:42
03/18/19
03/18
22:42
03/18/19
22:42
Hot Stocks
Western Union to partner with emerging-market moble network Thunes »

Western Union has teamed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$28.17

0.09 (0.32%)

22:40
03/18/19
03/18
22:40
03/18/19
22:40
Hot Stocks
Mylan conducts voluntary recall of Levoleucovorin Injection »

Mylan Institutional LLC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYHT

Shineco

$0.67

0.0003 (0.04%)

20:43
03/18/19
03/18
20:43
03/18/19
20:43
Recommendations
Shineco analyst commentary  »

Shineco establishing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$44.97

0.33 (0.74%)

20:31
03/18/19
03/18
20:31
03/18/19
20:31
Hot Stocks
Activision Blizzard unveils Call of Duty: Mobile edition »

Activision, in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$372.10

-6.795 (-1.79%)

20:28
03/18/19
03/18
20:28
03/18/19
20:28
Hot Stocks
Boeing CEO says 'work progressing thoroughly' to understand cause for 737 crash »

In a letter, Boeing CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    May

GPX

GP Strategies

$12.57

-1.745 (-12.19%)

20:25
03/18/19
03/18
20:25
03/18/19
20:25
Recommendations
GP Strategies analyst commentary at Barrington »

GP Strategies organic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

MIK

Michaels

$11.79

0.11 (0.94%)

, DSW

DSW

$25.30

-0.09 (-0.35%)

20:25
03/18/19
03/18
20:25
03/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MIK

Michaels

$11.79

0.11 (0.94%)

DSW

DSW

$25.30

-0.09 (-0.35%)

HDS

HD Supply

$43.09

0.09 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

NVDA

Nvidia

$168.91

-0.99 (-0.58%)

, AMZN

Amazon.com

$1,742.00

29.29 (1.71%)

20:19
03/18/19
03/18
20:19
03/18/19
20:19
Hot Stocks
Nvidia to partner with Amazon on bringing AI to connected devices »

NVIDIA (NVDA) announced a…

NVDA

Nvidia

$168.91

-0.99 (-0.58%)

AMZN

Amazon.com

$1,742.00

29.29 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 19

    Mar

  • 20

    Mar

  • 26

    Mar

  • 04

    Apr

MEOH

Methanex

$57.22

1.68 (3.02%)

19:57
03/18/19
03/18
19:57
03/18/19
19:57
Hot Stocks
Methanex confirms M&G Investment letter, urges shareholders take no action »

Methanex confirms that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HDS

HD Supply

$43.09

0.09 (0.21%)

19:55
03/18/19
03/18
19:55
03/18/19
19:55
Earnings
HD Supply sees FY19 EPS $3.52-$3.81, consensus $3.64 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 27

    Mar

HDS

HD Supply

$43.09

0.09 (0.21%)

19:53
03/18/19
03/18
19:53
03/18/19
19:53
Earnings
HD Supply sees Q1 EPS 75c-84c, consensus 85c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 27

    Mar

HDS

HD Supply

$43.09

0.09 (0.21%)

19:52
03/18/19
03/18
19:52
03/18/19
19:52
Earnings
HD Supply reports Q4 adjusted EPS 70c, consensus 67c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 27

    Mar

CASA

Casa Systems

$8.89

-0.06 (-0.67%)

19:47
03/18/19
03/18
19:47
03/18/19
19:47
Initiation
Casa Systems initiated at DA Davidson »

Casa Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCI

Crown Castle

$124.67

-0.41 (-0.33%)

19:46
03/18/19
03/18
19:46
03/18/19
19:46
Downgrade
Crown Castle rating change at Deutsche Bank »

Crown Castle downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARPO

Aerpio Pharmaceuticals

$1.22

-2.915 (-70.58%)

19:39
03/18/19
03/18
19:39
03/18/19
19:39
Downgrade
Aerpio Pharmaceuticals rating change at Guggenheim »

Aerpio Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

LIVX

LiveXLive Media

$6.30

0.19 (3.11%)

19:37
03/18/19
03/18
19:37
03/18/19
19:37
Initiation
LiveXLive Media initiated at Maxim »

LiveXLive Media initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 30

    Apr

  • 01

    May

AKBA

Akebia

$8.19

0.01 (0.12%)

19:31
03/18/19
03/18
19:31
03/18/19
19:31
Recommendations
Akebia analyst commentary at Piper Jaffray »

Akebia investors should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

VALE

Vale

$13.28

0.11 (0.84%)

19:18
03/18/19
03/18
19:18
03/18/19
19:18
Periodicals
Vale to resume activities at port after court injunction, Reuters reports »

Vale said Friday that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

TROX

Tronox

$12.09

0.2 (1.68%)

19:00
03/18/19
03/18
19:00
03/18/19
19:00
Hot Stocks
Tronox to present National Titanium Dioxide deal to FTC »

Tronox confirmed that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYMTF

Hyundai Motor

$0.00

(0.00%)

, HYMLF

Hyundai Motor Co

$0.00

(0.00%)

18:58
03/18/19
03/18
18:58
03/18/19
18:58
Hot Stocks
Connecticut AG announces probe into Hyundai, Kia fires »

Connecticut Attorney…

HYMTF

Hyundai Motor

$0.00

(0.00%)

HYMLF

Hyundai Motor Co

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYNH

Syneos Health

$47.42

0.49 (1.04%)

, TLRY

Tilray

$72.15

-0.38 (-0.52%)

18:54
03/18/19
03/18
18:54
03/18/19
18:54
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

SYNH

Syneos Health

$47.42

0.49 (1.04%)

TLRY

Tilray

$72.15

-0.38 (-0.52%)

EOLS

Evolus

$23.80

-1.02 (-4.11%)

AMRS

Amyris

$3.83

-0.1 (-2.54%)

FOE

Ferro

$18.88

0.125 (0.67%)

REV

Revlon

$19.39

0.42 (2.21%)

AKBA

Akebia

$8.19

0.01 (0.12%)

TORC

ResTORbio

$8.97

0.27 (3.10%)

TACO

Del Taco

$10.60

0.47 (4.64%)

HQY

HealthEquity

$82.86

0.76 (0.93%)

CVTI

Covenant Transportation

$21.43

-0.4 (-1.83%)

YEXT

Yext

$23.00

0.33 (1.46%)

WAGE

WageWorks

$39.59

1.875 (4.97%)

TWO

Two Harbors

$14.26

0.07 (0.49%)

AGS

PlayAGS

$25.65

-0.89 (-3.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 19

    Mar

  • 19

    Mar

  • 21

    Mar

  • 17

    Apr

  • 16

    May

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

AAPL

Apple

$188.03

1.83 (0.98%)

18:52
03/18/19
03/18
18:52
03/18/19
18:52
Periodicals
Apple stops iOS 12.1.3 code signing after iOS 12.1.4 launch, AppleInsider says »

Apple has stopped signing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WP

Worldpay

$108.52

9.8 (9.93%)

, FIS

FIS

$108.14

-0.73 (-0.67%)

18:41
03/18/19
03/18
18:41
03/18/19
18:41
Downgrade
Worldpay, FIS rating change at BMO Capital »

Worldpay downgraded to…

WP

Worldpay

$108.52

9.8 (9.93%)

FIS

FIS

$108.14

-0.73 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 18

    Mar

  • 19

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 04

    Apr

ERIC

Ericsson

$9.56

-0.075 (-0.78%)

18:32
03/18/19
03/18
18:32
03/18/19
18:32
Hot Stocks
Ericsson selected by TDC to roll out commercial 5G in Denmark »

Ericsson has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.